Monopar Therapeutics - FORM 10-K - EX-23 - CONSENTS OF EXPERTS AND COUNSEL - March 25, 2021

Attached files

file filename
EX-31 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit31-2.htm
EX-10 - MATERIAL CONTRACTS - Monopar Therapeuticsprxconsulting2020agreemen.htm
EX-32 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - Monopar Therapeuticsexhibit32-1.htm
EX-31 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit31-1.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - Monopar Therapeuticsexhibit21-1.htm
EX-4 - INSTRUMENTS DEFINING THE RIGHTS OF SECURITY HOLDERS, INCLUDING INDENTURES INSTRU - Monopar Therapeuticsexhibit4-1.htm
10-K - PRIMARY DOCUMENT - Monopar Therapeuticsa10-k12312020.htm
 
 
 
Exhibit 23.1
 
 
Consent of Independent Registered Public Accounting Firm
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (333-235791) and on Form S-8 (333-235790 and 333-250046) of our report dated March 24, 2021, relating to the consolidated financial statements of Monopar Therapeutics Inc. as of December 31, 2020, which appears in this Annual Report on Form 10-K.
 
We also consent to the reference to us under the caption “Experts” in such Registration Statements.
 
 
 
 
 
/s/ BPM LLP
BPM LLP
 
Walnut Creek, California
 
March 24, 2021
 
 

Monopar Therapeutics Reports